Livergenix operates a data-driven drug discovery platform specifically targeting liver and metabolic health. The company utilizes precision biology and advanced data analytics to identify novel drug targets for conditions like MASLD. This focus accelerates the development of targeted therapies for complex metabolic and liver diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Drug development and precision medicine for Metabolic-dysfunction Associated Steatohepatitis (MASH) are hindered by a lack of comprehensive, high-quality clinical and multi-omics data, particularly from Asian patient populations. The limited availability of well-characterized liver specimens and longitudinal data restricts the ability to identify reliable biomarkers and develop effective therapies.
Solution
Livergenix is developing a proprietary data bio-banking platform that integrates longitudinal clinical data with multi-omics data from Asian patients with MASH. This platform provides access to ground-truth biology derived from rare and well-characterized liver specimens. By integrating diverse data sources, Livergenix enables a deeper understanding of liver biology and accelerates clinically driven discoveries. The platform aims to facilitate precision medicine approaches and the development of novel biomarkers and therapeutics for liver disease treatment.
Target Audience
The primary target audience includes researchers, pharmaceutical companies, and biotech firms involved in drug development, biomarker discovery, and precision medicine for liver and metabolic diseases.
Features
- Proprietary databank of clinical and multi-omics data from Asian MASH patients
- Longitudinal clinical data tracking disease progression and treatment outcomes
- Integration of multi-omics data including genomics, proteomics, and metabolomics
- Access to rare and well-characterized liver specimens
- AI-driven biomarker discovery